Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimerli (FYB201) vs Lucentis in Neovascular AMD
NCT02611778Phase 3Completed
- Sponsor
- Bioeq AG
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Bioeq AG. Started Dec 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02611778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611778.